RDFA
REGN icon

Ritter Daniher Financial Advisory’s Regeneron Pharmaceuticals REGN Stock Holding History

Ritter Daniher Financial Advisory’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-35
Closed -$24.9K – 325
2024
Q4 		$24.9K Sell
35
-4
-10% -$3.36K 0.01% 199
2024
Q3 		$41K Hold
39
– – 0.01% 174
2024
Q2 		$41K Hold
39
– – 0.01% 165
2024
Q1 		$37.5K Sell
39
-19
-33% -$18.1K 0.01% 169
2023
Q4 		$50.9K Hold
58
– – 0.02% 149
2023
Q3 		$47.7K Hold
58
– – 0.02% 145
2023
Q2 		$41.7K Hold
58
– – 0.02% 148
2023
Q1 		$47.7K Sell
58
-7
-11% -$5.28K 0.02% 140
2022
Q4 		$46.9K Buy
+65
New +$48K 0.02% 150

Other funds holding REGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ritter Daniher Financial Advisory's REGN Position: Q1 2025 in Review

Ritter Daniher Financial Advisory sold out of Regeneron Pharmaceuticals (REGN) in Q1 2025, closing a stake of 35 shares — an estimated $24.9K sold.

Ritter Daniher Financial Advisory first reported a position in REGN in Q4 2022 and held it in 9 quarters. The position peaked at $50.9K in Q4 2023. 1,290 funds tracked by Wall St. Rank hold REGN as of Q1 2025.

  • Ritter Daniher Financial Advisory reported no remaining Regeneron Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Ritter Daniher Financial Advisory sold 35 Regeneron Pharmaceuticals shares in Q1 2025, an estimated $24.9K.
  • Ritter Daniher Financial Advisory first reported a position in Regeneron Pharmaceuticals in Q4 2022 and held it in 9 quarters.
  • Ritter Daniher Financial Advisory's Regeneron Pharmaceuticals position peaked at $50.9K in Q4 2023.
  • 1,290 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2025.

Based on Ritter Daniher Financial Advisory's 13F filing for Q1 2025, filed 9 May 2025.